Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in Advanced NSCLC
NCT07105176Phase 1Recruiting
- Sponsor
- Huasai Biomedicine
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-IT101 in non-small cell lung cancer (NSCLC), sponsored by Huasai Biomedicine. Primary endpoints: Adverse Events at 12 months, Serious Adverse Events at 12 months and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
HS-IT101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07105176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105176.